Connect with us

Cannabis News

How to Unf**k American Drug Laws

Published

on


fix american drug laws

How to Unf**k America!

DISSOLVE THE DEA AND RE-NEGOTIATE DRUG AGREEMENTS WORLDWIDE!

The Drug Enforcement Administration (DEA) has long been a staunch opponent of cannabis legalization, so it comes as no surprise that they’ve rejected the Department of Health and Human Services’ (HHS) recommendation to reschedule cannabis to Schedule III under the Controlled Substances Act. The HHS review found cannabis to have medical value and a lower potential for abuse than currently scheduled.

 

However, the DEA believes the agency is wrong on this front.

 

This stance is unsurprising given the DEA’s role as the enforcer of drug laws that has largely criminalized cannabis for decades. Their opposition protects the interests of the powerful pharmaceutical industry which stands to lose billions if cannabis is rescheduled and medical programs expand.

 

It’s estimated that wherever medical cannabis is legalized, pharma loses roughly $10 billion in annual revenues as patients switch from prescription drugs to medical marijuana.

 

The DEA’s rejection of rescheduling leaves America at a crossroads. Do we continue allowing an agency with a vested interest in maintaining cannabis prohibition to override scientific evidence on the plant’s medical value? Or do we re-evaluate the necessity of the DEA’s existence altogether?

 

This antiquated drug war institution has not only perpetuated injustices against cannabis consumers but has also contributed to policies that make illicit substances even more unsafe and available on the black market. By clinging to an ideology focused on criminalization over harm reduction, the DEA’s presence is increasingly antithetical to the ideals of a free society.

 

As America reckons with the DEA’s hardline position, it’s worth examining whether disbanding the agency entirely and renegotiating international drug policies could be the first step in “unf**king” the nation’s catastrophic war on drugs. This article aims to showcase these reform ideas and a path forward.

 

 

While anonymous sources cited in the Wall Street Journal report claim there is tension between certain DEA officials and the White House over marijuana’s scheduling status, the agency itself has not taken an official public position on the matter.

 

The DEA has only stated that it is currently carrying out its scientific and medical evaluation of cannabis as required by law after receiving a scheduling recommendation from the U.S. Department of Health and Human Services (HHS).

 

HHS conducted its own assessment and advised moving marijuana from its current restrictive Schedule I status to the less prohibitive Schedule III under the Controlled Substances Act.

 

In testimony before Congress last year, DEA Administrator Anne Milgram said the agency would “keep an open mind” and “look at all the research” during its review process. This suggests the DEA has not pre-judged the outcome and is withholding any scheduling decision until it has thoroughly examined the evidence.

 

Importantly, the DEA has stressed that as the agency tasked with enforcing the Controlled Substances Act, it maintains final authority over determining cannabis’ proper scheduling – not HHS. While the Congressional Research Service stated it is “likely” DEA will accept HHS’ Schedule III recommendation based on past precedent, the DEA is not legally bound to that advisory opinion.

 

The purported resistance from some DEA officials cited anonymously aligns with the historical position of the agency and its past administrators who have vigorously defended marijuana’s Schedule I status quo. For example, the quote in the Journal from former DEA head Timothy Shea asserting “the science does not support rescheduling” reflects this entrenched anti-rescheduling mindset.

 

However, the DEA has made no definitive public statement adopting or rejecting HHS’ scheduling recommendation to date. All the agency has officially communicated is that it is presently conducting “an appropriate review of the science and available data” related to marijuana’s abuse potential, risk to public health, and medical value as required under the Controlled Substances Act.

 

In fact, Administrator Milgram pointedly declined to even acknowledge if there is any internal dissent when asked about the Journal’s reporting, telling Marijuana Moment: “I’m not going to comment on any internal DEA deliberations.”

 

Some cannabis reform advocates have expressed skepticism about the motivations behind the anonymously-sourced leaks claiming DEA opposition, especially given the consistent anti-rescheduling history and drug war ethos of the agency. As NORML’s deputy director stated, there’s a presumed faction within DEA that wishes to “cling to their ‘flat Earth’ cannabis policies at all costs” regardless of the evidence.

 

While this apparent internal wariness about rescheduling aligns with the DEA’s historic stance, the agency’s official public position for now is that it is dutifully carrying out the scheduling review process as required with an open mind. Definitive proof of whether the DEA will accept or reject HHS’ recommendation to reschedule cannabis to Schedule III is still pending completion of its evaluation in the coming months.

 

 

The Drug Enforcement Administration’s own mission statement makes clear that the agency’s purpose is to enforce the controlled substances laws and regulations of the United States. However, the DEA has catastrophically failed to achieve those objectives over the past several decades of waging its self-described “war on drugs.”

 

According to the DEA’s mission statement, the agency is tasked with “bringing to the criminal and civil justice system…organizations involved in the growing, manufacture, or distribution of controlled substances.” Yet despite an increasingly militarized effort and violating civil liberties in the name of this “war,” illicit drugs are more widely available and used today than when the modern Controlled Substances Act was established in 1970.

 

One key reason the DEA has been losing this war is because the Controlled Substances Act essentially grants a monopoly over the “manufacturing of Schedule I drugs” solely to well-funded pharmaceutical corporations and research institutions. By wrongfully placing cannabis in the most restrictive Schedule I category, the DEA has made it nearly impossible for anyone outside of big pharma to legally research and develop drugs derived from the plant.

 

This monopolistic blockade goes against stated American principles of facilitating open research, scientific inquiry, and a free market of innovative new medications. Instead, it protects the profit motives of large pharmaceutical companies by eliminating potential competition from cannabis-derived drugs and therapies.

 

Despite an overwhelming body of scientific evidence showing cannabis’ relative safety and potential medical benefits, the DEA stubbornly clings to antiquated dogmas labeling it a dangerous substance “with no currently accepted medical use.” This ideological inflexibility seems motivated more by a desire for the DEA’s own bureaucratic relevance than upholding facts, ethics or American principles.

 

After over 50 years and over $1 trillion spent enforcing draconian drug laws, it’s clear that the DEA’s militarized “war” has been an extraordinarily costly and tragic failure in terms of public health, civil liberties and human rights. Not only has prohibition caused a crisis of overincarceration, but it has also empowered violent criminal cartels while failing to reduce drug availability or use.

 

In the 1970s when the modern war on drugs was launched, around 25 million Americans had used illicit drugs. Today, after a trillion dollars spent on DEA enforcement efforts, over 119 million Americans have used prohibited substances according to federal data. Rather than reducing availability and use, drugs are unquestionably more prevalent across all demographics than before the DEA’s creation.

 

Not only has the DEA’s drug war failed to reduce drug use, but it has enriched and further empowered the highly organized, well-resourced, and increasingly ruthless criminal cartels that control the lucrative illegal drug trade. Before the harsh prohibitions, drug operations were unrefined and largely limited to small crime rings. But cartels grew into the multinational billion-dollar enterprises they are today precisely because of the high-risk, high-reward economics created by blanket criminalization.

 

Essentially, the DEA’s drug enforcement policies turbocharged the profitable international drug trade into a full-blown cartel-controlled battlefield with thousands of lives lost in drug-related violence every year. In many regions, murderous cartels exert more control than governments due to the lawlessness and fortunes enabled by harsh prohibition.

 

Simply put, the DEA has undeniably lost its militarized crusade to extinguish drug use and suppress drug supply through harsh criminalization. It is clear that continued prohibition and DEA enforcement actually makes drugs more available, more potent, more adulterated with dangerous additives, and more consolidated under the control of bloodthirsty criminal enterprises.

 

Since the DEA has manifestly failed in its purported core mission after a half-century of trying the same unsuccessful strong-arm tactics, it’s time for America to radically renegotiate its relationship with drugs and drug policy. Clinging to this quixotic, destructive “war on drugs” only perpetuates injustice, enriches murderous criminals, erodes civil liberties, inhibits research into potential cures, and debases America’s founding ideals.

 

The first step in renegotiating this relationship is ending the DEA’s fundamentally flawed, uniquely American strain of blanket drug criminalization that gifted cartels their very power and riches. Only then can the nation reclaim its principles and pragmatically regulate drugs in a manner that improves public health and safety.

 

 

The inescapable reality is that the DEA’s prohibitionist policies have utterly failed to curb drug use, availability or the power of violent criminal cartels. In fact, the evidence shows their harsh crackdown tactics have made the drug supply more dangerous and emboldened criminality. This raises the uncomfortable but imperative question – is the DEA itself more detrimental to America’s overall health and wellness than the drugs it futilely aims to eliminate?

 

By decentralizing drug policy away from the DEA’s one-size-fits-all criminalization model, America can open the door to responsibly exploring therapeutic psychotropics like psilocybin and LSD. These could provide psychiatric breakthroughs, yet their potential remains bottlenecked by the DEA’s restrictive drug scheduling system which fuels a cruel cycle of patient suffering.

 

Disbanding the DEA does not mean descending into some Mad Max drug apocalypse fantasy peddled by drug warriors. Rather, it simply unlocks the gates restraining scientific inquiry into these substances’ medicinal wisdom for the betterment of society.

 

Moreover, America cannot continue moralizing about illicit drugs being universally “bad” while simultaneously celebrating mind-altering drugs like alcohol that are scientifically more toxic and lethal than cannabis. This blatant hypocrisy and muddled messaging undermines credibility. Alcohol objectively fits the profile of a Schedule I narcotic far more than marijuana, yet it’s aggressively marketed during events like the Super Bowl while the DEA places its watchful eye on those seeking alternative paths outside the mainstream river of pharmaceutical junk.

 

For those adamant about “unfucking America,” one of the most imperative first steps is dismantling the DEA power structure and reclaiming individual bodily autonomy from the state’s draconian prohibition regime. America’s founders envisioned a society of personal freedoms, not one where federal foot soldiers infringe on liberties under the prejudiced guise of keeping “dangerous” plants from citizens who wish to consciously explore their own consciousness.

 

THE DEA ON CANNABIS, READ ON…

THE DEA VS CANNABIS

THE DEA VS SCIENCE ON CANNABIS BENEFITS!



Source link

Cannabis News

How Do You Stop Lab-Shopping for the Highest THC Results?

Published

on

By


single lab test for cannabis THC results

In a decisive move aimed at bolstering consumer safety and ensuring the integrity of cannabis products, Massachusetts regulators have mandated that all cannabis products must undergo testing at a single, licensed laboratory. This new regulation comes in response to the growing issue of “lab shopping,” where cannabis producers seek favorable testing results by sending their products to multiple laboratories. The Massachusetts Cannabis Control Commission (CCC) announced this significant regulatory change after extensive consultations with industry stakeholders, public health officials, and consumer advocates.

 

This article explores the implications of this regulation for the cannabis industry, consumers, and public health. It also examines the broader context of cannabis regulation in Massachusetts and the potential impact of this decision on the future of the state’s cannabis market.

 

Understanding Lab Shopping

 

 What is Lab Shopping?

 

Lab shopping refers to the practice where cannabis producers send their products to various testing laboratories in search of the most favorable results. Producers may choose labs based on their reputation for leniency or their history of providing positive results. This behavior can lead to significant discrepancies in product safety assessments and quality assurance.

 

The Risks Associated with Lab Shopping

 

1. Consumer Health Risks: The primary concern surrounding lab shopping is the potential risk it poses to consumer health. Inconsistent testing results mean that products containing harmful contaminants—such as pesticides, heavy metals, or mold—may be sold without proper scrutiny. This can lead to serious health issues for consumers who unknowingly purchase tainted products.

 

2. Market Integrity: Lab shopping undermines the integrity of the legal cannabis market. When consumers cannot trust that products have been tested rigorously and uniformly, it erodes confidence in legal cannabis sales and can drive customers back to illicit markets where safety standards are nonexistent.

 

3. Regulatory Challenges: For regulators like the CCC, lab shopping complicates enforcement efforts. It becomes increasingly difficult to monitor compliance when producers can easily switch labs to obtain favorable results, making it challenging to ensure that all products meet established safety standards.

 

The Regulatory Response

 

The Role of the Cannabis Control Commission (CCC)

 

The Massachusetts Cannabis Control Commission is tasked with regulating the state’s cannabis industry. As part of its mandate, the CCC has worked diligently to establish a comprehensive regulatory framework that governs various aspects of cannabis production and sale. However, as the industry has evolved, so too have the challenges associated with ensuring product safety and quality.

 

In light of growing concerns about lab shopping and its implications for public health and safety, the CCC recognized the need for a more robust regulatory framework. After extensive discussions with industry stakeholders and public health officials, the commission concluded that a single-lab testing requirement was necessary to address these issues effectively.

 

Implementation of Single-Lab Testing

 

In late 2023, following thorough deliberation and stakeholder engagement, the CCC announced its new regulation mandating that all cannabis products must be tested by a single licensed laboratory before they can be sold to consumers. This decision aims to achieve several key objectives:

 

  • Standardize Testing Protocols: By requiring that all products be tested by a single lab, regulators can ensure that all products are subject to consistent testing standards. This uniformity is crucial for maintaining product quality and safety across the market.

 

  • Enhance Accountability: A single-lab requirement makes it easier for regulators to hold laboratories accountable for their testing practices. If discrepancies arise in testing results, it will be clear which laboratory conducted the tests, facilitating more straightforward investigations.

 

  • Improve Consumer Confidence: With consistent testing results across all products, consumers can feel more secure in their purchases. This increased confidence is vital for fostering a healthy legal cannabis market in Massachusetts.

 

 Implications of Single-Lab Testing

 

For Producers

 

1. Increased Accountability: Producers will need to establish relationships with specific laboratories and ensure that their products meet stringent quality standards before submission for testing. This shift will require producers to invest more in quality control measures throughout their production processes.

 

2. Potential Cost Implications: While single-lab testing may streamline processes for some producers, it could also lead to increased costs if producers are required to pay higher fees for comprehensive testing services. Smaller producers may find it particularly challenging to absorb these costs.

 

3. Adaptation Period: Producers will need time to adjust their operations and supply chains to comply with this new regulation. This may involve reevaluating partnerships with existing labs or investing in new quality control measures.

 

4. Impact on Product Development: The requirement for single-lab testing may also influence how producers develop new products. With fewer laboratories available for testing, producers may need to plan their product launches more carefully and allow additional time for testing processes.

 

For Laboratories

 

1. Increased Demand for Services: Licensed laboratories may experience an increase in demand as producers consolidate their testing needs with fewer facilities. This could lead to higher revenues for labs but also increased pressure on them to maintain high-quality standards amidst growing workloads.

 

2. Need for Enhanced Capabilities: Laboratories will need to ensure they have the capacity and technology necessary to handle increased volumes of samples while maintaining rigorous quality control measures. This may require investments in new equipment or hiring additional staff.

 

3. Regulatory Compliance: Laboratories will face heightened scrutiny from regulators as they become key players in ensuring product safety. They will need to demonstrate compliance with all relevant regulations and maintain transparent practices regarding their testing methodologies.

 

 For Consumers

 

1. Improved Product Safety: The primary benefit for consumers is enhanced safety assurance. With standardized testing protocols in place, consumers can trust that cannabis products have been thoroughly vetted for contaminants and potency before reaching store shelves.

 

2. Greater Transparency: As part of this regulatory shift, there may be increased transparency regarding testing results and laboratory practices. Consumers will have access to clearer information about what goes into their cannabis products, empowering them to make informed choices.

 

3. Potential Price Increases: While improved safety is paramount, there is a possibility that compliance costs could be passed on to consumers through higher prices for cannabis products. Producers may need to adjust their pricing structures in response to increased operational costs associated with single-lab testing.

 

Cannabis Regulation in Massachusetts

 

 Historical Overview

 

Massachusetts was one of the first states in New England to legalize recreational cannabis use following the passage of Question 4 in 2016. The legalization marked a significant shift in public policy and opened up a new economic sector within the state. However, as with any emerging industry, challenges quickly arose—particularly concerning product safety and quality assurance.

 

Existing Regulatory Framework

 

Prior to the introduction of single-lab testing regulations, Massachusetts had established a comprehensive regulatory framework governing various aspects of cannabis production and sale:

 

 

 

 

Despite these measures, lab shopping highlighted gaps in enforcement and compliance that necessitated further action from regulators.

 

 Industry Reactions

 

Support from Public Health Advocates

 

Public health advocates have largely welcomed the CCC’s decision to implement single-lab testing as a crucial step toward safeguarding public health by ensuring that all cannabis products meet consistent safety standards. Many believe this regulation will help prevent contaminated or substandard products from reaching consumers while bolstering trust in legal cannabis sales.

 

Dr. Emily Thompson, a public health expert at Harvard University, stated, “This regulation is essential for protecting consumers from potential health risks associated with contaminated cannabis products.”

 

Concerns from Industry Stakeholders

 

Conversely, some industry stakeholders have expressed concerns about potential drawbacks:

 

1. Operational Challenges: Smaller producers may find it difficult to navigate relationships with larger laboratories or face delays in getting their products tested due to increased demand at those facilities.

  

2. Innovation Stifling: Critics argue that requiring single-lab testing could stifle innovation within the industry by limiting producers’ options for exploring different testing methodologies or technologies offered by various labs.

 

3. Market Dynamics: There are worries that this regulation could create monopolistic tendencies within laboratory services if only a few labs dominate the market due to increased demand from producers seeking reliable test results.

 

4. Impact on Small Businesses: Small-scale cultivators might struggle more than larger companies due to limited resources and access to high-quality labs capable of meeting stringent requirements without significantly raising costs.

 

 Future Outlook

 

As Massachusetts implements this new regulation mandating single-lab testing for all cannabis products sold within its borders, it sets an important precedent that other states may consider as they navigate similar challenges within their own burgeoning cannabis markets.

 

Potential National Implications

 

The decision by Massachusetts regulators could influence national discussions around cannabis regulation as other states look toward creating frameworks that prioritize consumer safety while fostering industry growth:

 

  1. Increased Interest from Other States: States grappling with similar issues related to lab shopping may look closely at Massachusetts’ approach as they develop their own regulations.

 

  1. Collaboration Among States: As states continue legalizing recreational marijuana use across the country, there may be opportunities for collaboration on best practices regarding product safety standards and laboratory oversight.

 

  1. Federal Considerations: With ongoing discussions about federal legalization of marijuana gaining traction nationally—especially amid shifting political landscapes—regulatory models like those emerging from Massachusetts could serve as templates for future federal guidelines governing cannabis production and sale across state lines.

 

 Conclusion

 

The Massachusetts Cannabis Control Commission’s mandate for single-lab testing represents a pivotal shift in evaluating cannabis products for safety and quality assurance within one of the nation’s most dynamic legal marijuana markets. By targeting the issue of lab shopping, this regulation prioritizes consumer protection, aiming to enhance public health outcomes and rebuild confidence in the safety of legalized cannabis products. While the transition poses challenges for producers adapting operational processes and laboratories scaling their capabilities, the regulation seeks to balance fostering innovation in an evolving industry with rigorous oversight mechanisms. As Massachusetts refines its regulatory framework, balancing the interests of regulators and profit-driven stakeholders, collaboration will be essential to thriving under these new guidelines. This change not only advances the state’s cannabis sector but also sets a potential standard for other states to ensure safe consumption and responsible business practices in the growing marijuana industry.

 

LAB SHOPPING FOR HIGH THC RESULTS? READ ON…

CANNABIS LAB SHOPPING FOR THC

LAB SHOPPING FOR THC RESULTS- THE DIRTY SECRET IN CANNABIS!



Source link

Continue Reading

Cannabis News

Happy Holidays from The Canna Law Blog

Published

on

By


Wishing all of our readers, along with friends and families, the very best this holiday season.

Whether you celebrate Hanukkah, Christmas, Kwanzaa, Winter Solstice, Festivus, or something else, we hope you can kick back and enjoy this wonderful time of the year.

The post Happy Holidays from The Canna Law Blog appeared first on Harris Sliwoski LLP.



Source link

Continue Reading

Cannabis News

5 Cannabis Christmas Recipes to Try This Holiday Season at Home or the Office Party!

Published

on

By


cannabis christmas recipes

Ah yes, it’s that magical time of year again when Ganja Clause slides down the chimney to visit all the good little stoners. The lights are twinkling, the fire is crackling, and the sweet aroma of cannabis-infused treats fills the air. As someone who’s spent years experimenting with cannabis cuisine, I’ve learned that the holidays present the perfect opportunity to elevate traditional recipes to new heights.

To help make your holidaze more “dazey,” I’ve crafted five festive recipes that combine seasonal favorites with our favorite herb. These dishes aren’t just about getting high – they’re about creating memorable experiences and new traditions. But before we dive in, I need to emphasize something crucial: dosing is always important, and you should NEVER give these recipes to anyone without their explicit consent. While sharing is caring, tricking someone into consuming cannabis is not only unethical but potentially illegal. Always clearly label your infused treats and keep them safely away from children and unsuspecting guests.

With those important notes out of the way, let’s get into these magical recipes that will make your holiday season extra special.

Look, we all know eggnog is a holiday staple, but why not kick it up a notch? This cannabis-infused version will have you feeling jolly in no time. Just remember – this isn’t your grandma’s recipe (unless your grandma is really cool).

What You’ll Need:

  • 4 cups milk (or non-dairy alternative if that’s your jam)

  • 1 cup heavy cream (or coconut cream for you plant-based folks)

  • 6 egg yolks (fresh is best, trust me)

  • 1/2 cup sugar

  • 1 tsp vanilla extract

  • 1/2 tsp ground nutmeg

  • 1 tbsp cannabis tincture or cannabis-infused syrup

The Magic Process:

  1. Start by heating your milk and cream in a saucepan. You want it hot but not boiling – we’re making eggnog, not scrambled eggs.

  2. In a separate bowl, whisk those egg yolks, sugar, and vanilla until they’re well combined and looking smooth.

  3. Here’s the tricky part: slowly (and I mean SLOWLY) add the hot milk mixture to your egg mixture while whisking constantly. If you dump it all in at once, you’ll end up with sweet scrambled eggs, and nobody wants that.

  4. Pour everything back into your saucepan and cook over medium heat, stirring constantly until it thickens enough to coat the back of a spoon.

  5. Remove from heat, stir in that nutmeg, and let it cool a bit before adding your cannabis tincture or syrup.

  6. Chill thoroughly before serving.

Pro tip: Start with a small serving – this stuff can creep up on you!

Want to elevate your holiday meal? This gravy will take your feast to new heights. It’s perfect for drowning those mashed potatoes or smothering that turkey.

The Goods:

  • 2 cups chicken or vegetable stock

  • 1/4 cup all-purpose flour

  • 1/4 cup cannabis butter (cannabutter)

  • 1/2 tsp salt

  • 1/4 tsp black pepper

  • 1 tbsp chopped fresh herbs (thyme or rosemary work great)

The How-To:

  1. Melt your cannabutter over medium heat in a saucepan. Watch it carefully – burnt butter is not the vibe we’re going for.

  2. Whisk in the flour to create your roux. Cook it for about 1-2 minutes to get rid of that raw flour taste.

  3. Now, slowly pour in your stock while whisking like your life depends on it. No lumps allowed!

  4. Add your seasonings and herbs.

  5. Keep stirring and simmering until it reaches your desired thickness.

  6. Taste and adjust seasonings if needed (before you get too lifted).

Remember: Label this clearly! You don’t want Aunt Martha accidentally pouring this all over her plate without knowing what’s up.

Forget that canned stuff – this homemade cranberry sauce with a special twist will have everyone at the table asking for seconds (though you might want to limit them to just one serving).

The Ingredients:

Getting Saucy:

  1. Toss your cranberries, OJ, and sugar into a saucepan over medium heat.

  2. Let it cook until those cranberries start popping like tiny little fireworks (about 10 minutes).

  3. Once it’s thickened up nicely, remove from heat.

  4. Here comes the fun part – stir in your cannabis-infused honey or tincture.

  5. Let it cool completely before serving.

Pro tip: Make two batches – one regular and one infused. Just make sure to label them clearly!

These aren’t your regular sweet potatoes – they’re elevated sweet potatoes. Perfect for getting baked while getting baked.

What You Need:

  • 4 large sweet potatoes

  • 1/2 cup cannabis butter (cannabutter)

  • 1/4 cup brown sugar

  • 1 tsp ground cinnamon

  • 1/2 tsp ground nutmeg

  • Salt to taste

  • Marshmallows (optional, but highly recommended)

The Method:

  1. Preheat your oven to 375°F (190°C).

  2. Bake those sweet potatoes until they’re tender (about an hour).

  3. Once they’re cool enough to handle, peel and mash them up.

  4. Mix in your cannabutter, brown sugar, and spices.

  5. Transfer to a baking dish.

  6. If you’re feeling extra, top with marshmallows.

  7. Bake for another 20-30 minutes until everything’s golden brown and gorgeous.

Warning: These are dangerously delicious – pace yourself!

This warm, spicy cider will lift your spirits in more ways than one. Perfect for those chilly winter nights.

The Essentials:

The Process:

  1. Pour your cider into a large pot.

  2. Add your cinnamon sticks, cloves, and orange slices.

  3. Heat until it just starts to bubble, then reduce to a simmer.

  4. Add your cannabis-infused maple syrup (or add tincture to individual cups for controlled dosing).

  5. Let everything mingle and get cozy for about 20 minutes.

  6. Serve it up warm with an orange slice or cinnamon stick garnish.

Pro tip: Keep a non-infused batch warming for designated drivers and non-partaking guests.

Remember folks, the key to a successful Dankmas feast is clear labeling and careful dosing. Nothing ruins a holiday gathering quite like someone getting unexpectedly zooted. Happy cooking, and may your holidays be dank and delightful!

There you have it, folks – five unique ways to spice up your Dankmas traditions and make the season truly memorable. As someone who’s hosted many cannabis-friendly holiday gatherings, I can’t stress enough the importance of starting slow with these recipes. Edibles can take anywhere from 30 minutes to two hours to fully kick in, and you definitely don’t want to overdo it during family dinner. I strongly recommend doing a test run with different dosages before the big day to find your sweet spot.

What I love most about these recipes is that they offer a fantastic alternative for those looking to skip the traditional alcohol-heavy holiday celebrations. Cannabis provides a more natural way to unwind and connect with loved ones during this special time of year. Plus, you won’t have to worry about a hangover the next morning!

Remember to celebrate responsibly, be open about what’s infused and what isn’t, and most importantly, enjoy the magic of the season. Happy Dankmas to all, and to all a good height!

 

MORE DANKMAS STORIES, READ ON…

GANJA CLAUSE

THE NIGHT BEFORE CHRISTMAS BY GANJA CLAUSE!



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media